Abstract
Diabetes mellitus is a metabolic disease affecting millions of people worldwide. Hyperglycemia is the hallmark of all kind of diabetes including Type 1, 2 and gestational diabetes. Long term hyperglycemia can lead to macrovascular and microvascular complications such as cardiovascular diseases, renal disorders, neuropathic disorders like diabetic foot ulcers and retinopathy. This can be prevented by altering the lifestyle and by using therapeutic agents. These therapeutic agents are either chemically or biologically synthesized or obtained from natural sources like plants or microbes. Recent studies have shown that gut microbiota has a role in development of metabolic diseases. Also many new strategies have been suggested, using probiotics or microbial formulations to treat such diseases. There are several secondary metabolites currently in use for the treatments of diabetes and its complications and many small molecules have been identified which are potential therapeutics. In this chapter, we discuss about microbes, microbial products and genetically engineered microbes and its mechanisms for the treatment of diabetes and its comorbidities.
| Original language | English |
|---|---|
| Title of host publication | Microbial Biotechnology |
| Editors | J. Patra , G. Das, HS. Shin |
| Number of pages | 11 |
| Place of Publication | Singapore |
| Publisher | Springer Singapore |
| Publication date | 15 Feb 2018 |
| Pages | 383-393 |
| ISBN (Print) | 978-981-10-7139-3 |
| ISBN (Electronic) | 978-981-10-7140-9 |
| Publication status | Published - 15 Feb 2018 |
| MoE publication type | A3 Book chapter |
Bibliographical note
NFields of Science
- 3111 Biomedicine